Concepts (249)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Ophthalmology | 11 | 2023 | 560 | 2.560 |
Why?
|
Oculomotor Muscles | 14 | 2024 | 405 | 2.360 |
Why?
|
Oculomotor Nerve Diseases | 5 | 2022 | 53 | 1.600 |
Why?
|
Eye Injuries | 6 | 2023 | 227 | 1.580 |
Why?
|
Retinoblastoma | 8 | 2024 | 321 | 1.540 |
Why?
|
Vision, Binocular | 10 | 2024 | 225 | 1.520 |
Why?
|
Ophthalmologic Surgical Procedures | 13 | 2024 | 354 | 1.480 |
Why?
|
Strabismus | 7 | 2024 | 320 | 1.450 |
Why?
|
Eye Diseases | 4 | 2022 | 658 | 1.290 |
Why?
|
Hyphema | 4 | 2021 | 26 | 1.250 |
Why?
|
Eye Injuries, Penetrating | 4 | 2022 | 121 | 1.240 |
Why?
|
Esotropia | 5 | 2024 | 99 | 1.200 |
Why?
|
Retinal Neoplasms | 6 | 2024 | 151 | 0.990 |
Why?
|
Brain Concussion | 6 | 2022 | 1436 | 0.970 |
Why?
|
Exotropia | 2 | 2022 | 64 | 0.920 |
Why?
|
Post-Concussion Syndrome | 3 | 2022 | 257 | 0.900 |
Why?
|
Botulinum Toxins, Type A | 5 | 2024 | 238 | 0.850 |
Why?
|
Convergence, Ocular | 2 | 2021 | 26 | 0.830 |
Why?
|
Ocular Motility Disorders | 2 | 2022 | 144 | 0.760 |
Why?
|
Ocular Hypertension | 2 | 2021 | 211 | 0.750 |
Why?
|
Cataract | 2 | 2022 | 837 | 0.750 |
Why?
|
Accommodation, Ocular | 2 | 2021 | 47 | 0.680 |
Why?
|
Athletic Injuries | 4 | 2022 | 1245 | 0.640 |
Why?
|
Telemedicine | 5 | 2023 | 3110 | 0.620 |
Why?
|
Timolol | 1 | 2017 | 51 | 0.570 |
Why?
|
Granuloma, Pyogenic | 1 | 2017 | 47 | 0.550 |
Why?
|
Conjunctival Diseases | 1 | 2017 | 109 | 0.520 |
Why?
|
Orbit | 3 | 2021 | 459 | 0.500 |
Why?
|
Periosteum | 1 | 2014 | 139 | 0.450 |
Why?
|
Infarction | 1 | 2014 | 247 | 0.430 |
Why?
|
Body Fluids | 1 | 2014 | 322 | 0.410 |
Why?
|
Nose | 2 | 2022 | 524 | 0.390 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2017 | 1243 | 0.370 |
Why?
|
Polymers | 1 | 2017 | 1632 | 0.330 |
Why?
|
Melphalan | 3 | 2017 | 421 | 0.320 |
Why?
|
Child | 29 | 2024 | 80960 | 0.310 |
Why?
|
Lens, Crystalline | 2 | 2014 | 387 | 0.310 |
Why?
|
Glaucoma | 2 | 2022 | 1194 | 0.310 |
Why?
|
Biocompatible Materials | 1 | 2017 | 1703 | 0.300 |
Why?
|
Phacoemulsification | 1 | 2010 | 151 | 0.300 |
Why?
|
Lens Implantation, Intraocular | 1 | 2010 | 192 | 0.300 |
Why?
|
Retrospective Studies | 25 | 2024 | 81903 | 0.290 |
Why?
|
Visual Acuity | 6 | 2024 | 2714 | 0.270 |
Why?
|
Neuromuscular Agents | 3 | 2024 | 148 | 0.260 |
Why?
|
Anemia, Sickle Cell | 1 | 2014 | 1065 | 0.260 |
Why?
|
Macular Edema | 1 | 2010 | 387 | 0.250 |
Why?
|
Drug Delivery Systems | 1 | 2017 | 2238 | 0.250 |
Why?
|
Retinal Telangiectasis | 1 | 2024 | 26 | 0.230 |
Why?
|
Cranial Fossa, Middle | 1 | 2024 | 29 | 0.230 |
Why?
|
Ocular Hypotension | 1 | 2024 | 23 | 0.230 |
Why?
|
Durable Medical Equipment | 1 | 2023 | 23 | 0.220 |
Why?
|
Paralysis | 2 | 2022 | 250 | 0.220 |
Why?
|
Amblyopia | 2 | 2024 | 152 | 0.220 |
Why?
|
Arachnoid Cysts | 1 | 2024 | 60 | 0.220 |
Why?
|
Injections, Intramuscular | 3 | 2024 | 556 | 0.220 |
Why?
|
Optic Neuropathy, Ischemic | 2 | 2018 | 87 | 0.210 |
Why?
|
Humans | 63 | 2024 | 768970 | 0.210 |
Why?
|
Intraocular Pressure | 4 | 2024 | 1304 | 0.210 |
Why?
|
Cytomegalovirus Retinitis | 1 | 2022 | 56 | 0.210 |
Why?
|
Eye Pain | 1 | 2022 | 46 | 0.200 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3118 | 0.200 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3241 | 0.200 |
Why?
|
Hydrophthalmos | 1 | 2022 | 24 | 0.190 |
Why?
|
Child, Preschool | 14 | 2024 | 42683 | 0.190 |
Why?
|
Wounds, Nonpenetrating | 2 | 2021 | 807 | 0.190 |
Why?
|
Botulinum Toxins | 1 | 2022 | 190 | 0.180 |
Why?
|
Internship and Residency | 4 | 2022 | 5956 | 0.180 |
Why?
|
Vision Disorders | 2 | 2018 | 1093 | 0.180 |
Why?
|
Diabetic Retinopathy | 1 | 2010 | 1299 | 0.170 |
Why?
|
Trabeculectomy | 1 | 2022 | 174 | 0.170 |
Why?
|
Antineoplastic Agents, Alkylating | 2 | 2014 | 618 | 0.170 |
Why?
|
School Admission Criteria | 1 | 2020 | 107 | 0.170 |
Why?
|
Ophthalmic Artery | 2 | 2018 | 58 | 0.170 |
Why?
|
Sports Medicine | 1 | 2022 | 239 | 0.170 |
Why?
|
Hamartoma | 1 | 2022 | 236 | 0.170 |
Why?
|
Retinal Diseases | 2 | 2024 | 710 | 0.160 |
Why?
|
Uveitis | 1 | 2022 | 398 | 0.160 |
Why?
|
Personnel Selection | 1 | 2020 | 201 | 0.150 |
Why?
|
Lighting | 1 | 2020 | 210 | 0.150 |
Why?
|
Antifibrinolytic Agents | 1 | 2021 | 289 | 0.150 |
Why?
|
Infusions, Intra-Arterial | 1 | 2018 | 221 | 0.150 |
Why?
|
Diagnostic Techniques, Ophthalmological | 1 | 2020 | 251 | 0.150 |
Why?
|
Adolescent | 15 | 2024 | 89244 | 0.150 |
Why?
|
Pyridoxaminephosphate Oxidase | 1 | 2017 | 8 | 0.150 |
Why?
|
Infant | 11 | 2024 | 36556 | 0.140 |
Why?
|
Brain Diseases, Metabolic | 1 | 2017 | 44 | 0.140 |
Why?
|
Vulnerable Populations | 1 | 2022 | 718 | 0.140 |
Why?
|
Fisheries | 1 | 2017 | 48 | 0.140 |
Why?
|
Eye Foreign Bodies | 1 | 2017 | 51 | 0.140 |
Why?
|
Central Serous Chorioretinopathy | 1 | 2017 | 32 | 0.140 |
Why?
|
Anterior Chamber | 1 | 2017 | 194 | 0.140 |
Why?
|
Male | 32 | 2024 | 365203 | 0.140 |
Why?
|
Insurance, Health, Reimbursement | 1 | 2020 | 390 | 0.130 |
Why?
|
Fellowships and Scholarships | 2 | 2022 | 1134 | 0.130 |
Why?
|
Cross-Sectional Studies | 7 | 2024 | 26395 | 0.130 |
Why?
|
Drug Implants | 1 | 2017 | 230 | 0.130 |
Why?
|
Sports | 1 | 2022 | 703 | 0.130 |
Why?
|
Clinical Competence | 3 | 2022 | 4860 | 0.130 |
Why?
|
Confidentiality | 1 | 2020 | 606 | 0.130 |
Why?
|
Computer-Assisted Instruction | 1 | 2019 | 366 | 0.130 |
Why?
|
Edema | 2 | 2021 | 766 | 0.120 |
Why?
|
Stomatognathic System | 1 | 2014 | 4 | 0.120 |
Why?
|
Clavulanic Acid | 1 | 2014 | 19 | 0.120 |
Why?
|
Administration, Topical | 1 | 2017 | 704 | 0.120 |
Why?
|
Antineoplastic Agents | 2 | 2018 | 13698 | 0.120 |
Why?
|
Blue Toe Syndrome | 1 | 2014 | 4 | 0.120 |
Why?
|
Leukemia | 1 | 2022 | 1520 | 0.120 |
Why?
|
Pupil Disorders | 1 | 2014 | 33 | 0.120 |
Why?
|
Amnion | 1 | 2015 | 203 | 0.110 |
Why?
|
Retinopathy of Prematurity | 1 | 2019 | 449 | 0.110 |
Why?
|
Pandemics | 4 | 2023 | 8749 | 0.110 |
Why?
|
Drug Synergism | 1 | 2018 | 1762 | 0.110 |
Why?
|
Educational Measurement | 1 | 2020 | 1260 | 0.110 |
Why?
|
Documentation | 1 | 2020 | 917 | 0.110 |
Why?
|
Amoxicillin | 1 | 2014 | 182 | 0.110 |
Why?
|
Hypoxia-Ischemia, Brain | 1 | 2017 | 359 | 0.110 |
Why?
|
Stevens-Johnson Syndrome | 1 | 2015 | 232 | 0.100 |
Why?
|
Metals | 1 | 2017 | 713 | 0.100 |
Why?
|
Delayed-Action Preparations | 1 | 2017 | 969 | 0.100 |
Why?
|
Gait | 1 | 2018 | 822 | 0.100 |
Why?
|
Female | 24 | 2024 | 397515 | 0.100 |
Why?
|
Optic Nerve | 2 | 2021 | 571 | 0.100 |
Why?
|
Mass Casualty Incidents | 1 | 2014 | 180 | 0.100 |
Why?
|
Orbital Diseases | 1 | 2013 | 178 | 0.090 |
Why?
|
Treatment Outcome | 10 | 2024 | 65480 | 0.090 |
Why?
|
Periodicals as Topic | 1 | 2022 | 1470 | 0.090 |
Why?
|
Leukocyte Count | 1 | 2014 | 1609 | 0.090 |
Why?
|
History, 21st Century | 1 | 2017 | 1575 | 0.090 |
Why?
|
Catheterization, Peripheral | 1 | 2014 | 347 | 0.090 |
Why?
|
Blast Injuries | 1 | 2014 | 324 | 0.090 |
Why?
|
Internet | 1 | 2022 | 3112 | 0.090 |
Why?
|
Drug Therapy, Combination | 2 | 2024 | 6320 | 0.090 |
Why?
|
Immunologic Deficiency Syndromes | 1 | 2013 | 550 | 0.080 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2013 | 592 | 0.080 |
Why?
|
Follow-Up Studies | 6 | 2024 | 39394 | 0.080 |
Why?
|
Triamcinolone Acetonide | 1 | 2010 | 105 | 0.080 |
Why?
|
United States | 7 | 2023 | 73186 | 0.080 |
Why?
|
History, 20th Century | 1 | 2017 | 2771 | 0.080 |
Why?
|
Eye Movements | 2 | 2022 | 514 | 0.080 |
Why?
|
Hemangioma | 1 | 2013 | 727 | 0.080 |
Why?
|
Autoimmune Diseases | 1 | 2020 | 2258 | 0.070 |
Why?
|
Glucocorticoids | 2 | 2024 | 2167 | 0.070 |
Why?
|
Laser Coagulation | 1 | 2010 | 333 | 0.070 |
Why?
|
Face | 1 | 2013 | 1031 | 0.070 |
Why?
|
Pediatrics | 1 | 2022 | 3628 | 0.070 |
Why?
|
Brain Infarction | 1 | 2009 | 288 | 0.070 |
Why?
|
Physician-Patient Relations | 1 | 2020 | 3269 | 0.070 |
Why?
|
Combined Modality Therapy | 1 | 2018 | 8559 | 0.060 |
Why?
|
Proteins | 1 | 2020 | 6011 | 0.060 |
Why?
|
Medicare | 1 | 2023 | 6888 | 0.060 |
Why?
|
Income | 1 | 2023 | 1879 | 0.060 |
Why?
|
Blindness | 1 | 2009 | 587 | 0.060 |
Why?
|
Delivery of Health Care | 1 | 2022 | 5375 | 0.060 |
Why?
|
Optic Nerve Diseases | 2 | 2024 | 342 | 0.060 |
Why?
|
Acute Disease | 3 | 2024 | 7245 | 0.060 |
Why?
|
Microscopy, Acoustic | 1 | 2024 | 47 | 0.060 |
Why?
|
Seizures | 1 | 2017 | 3000 | 0.060 |
Why?
|
Atropine | 1 | 2024 | 244 | 0.060 |
Why?
|
Ciliary Body | 1 | 2024 | 168 | 0.050 |
Why?
|
Fossil Fuels | 1 | 2023 | 53 | 0.050 |
Why?
|
Eyeglasses | 1 | 2024 | 138 | 0.050 |
Why?
|
Refractive Errors | 1 | 2024 | 148 | 0.050 |
Why?
|
Papilledema | 1 | 2024 | 130 | 0.050 |
Why?
|
Diffusion Magnetic Resonance Imaging | 2 | 2018 | 2831 | 0.050 |
Why?
|
Emergency Medical Services | 1 | 2014 | 1947 | 0.050 |
Why?
|
Adult | 8 | 2023 | 223851 | 0.050 |
Why?
|
Epilepsy | 1 | 2017 | 3326 | 0.050 |
Why?
|
Fixation, Ocular | 1 | 2003 | 243 | 0.050 |
Why?
|
Optics and Photonics | 1 | 2003 | 307 | 0.050 |
Why?
|
Developing Countries | 1 | 2023 | 2911 | 0.050 |
Why?
|
Saccades | 1 | 2022 | 235 | 0.050 |
Why?
|
Vitreous Body | 1 | 2022 | 400 | 0.040 |
Why?
|
Inflammation | 1 | 2020 | 10868 | 0.040 |
Why?
|
Angiogenesis Inhibitors | 1 | 2010 | 2059 | 0.040 |
Why?
|
Endocrine System | 1 | 2020 | 113 | 0.040 |
Why?
|
Lipomatosis | 1 | 2020 | 112 | 0.040 |
Why?
|
Carbon Dioxide | 1 | 2023 | 1149 | 0.040 |
Why?
|
Specialty Boards | 1 | 2020 | 235 | 0.040 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2010 | 3518 | 0.040 |
Why?
|
Cohort Studies | 1 | 2021 | 41808 | 0.040 |
Why?
|
Bone Marrow Diseases | 1 | 2020 | 234 | 0.040 |
Why?
|
Bibliometrics | 1 | 2022 | 355 | 0.040 |
Why?
|
Pyridoxal Phosphate | 1 | 2017 | 123 | 0.040 |
Why?
|
Environment | 1 | 2023 | 1122 | 0.030 |
Why?
|
CD4 Lymphocyte Count | 1 | 2022 | 2598 | 0.030 |
Why?
|
Anti-Bacterial Agents | 1 | 2014 | 7478 | 0.030 |
Why?
|
Feedback | 1 | 2019 | 799 | 0.030 |
Why?
|
Young Adult | 4 | 2023 | 60131 | 0.030 |
Why?
|
Sirolimus | 1 | 2022 | 1540 | 0.030 |
Why?
|
Eye Enucleation | 1 | 2014 | 128 | 0.030 |
Why?
|
Explosive Agents | 1 | 2014 | 26 | 0.030 |
Why?
|
Bombs | 1 | 2014 | 73 | 0.030 |
Why?
|
Skin Neoplasms | 1 | 2013 | 5864 | 0.030 |
Why?
|
Injections, Intra-Arterial | 1 | 2013 | 181 | 0.030 |
Why?
|
Prospective Studies | 2 | 2023 | 54962 | 0.030 |
Why?
|
Magnetic Resonance Imaging | 3 | 2017 | 36854 | 0.030 |
Why?
|
Texas | 1 | 2014 | 410 | 0.030 |
Why?
|
Antibodies, Monoclonal | 1 | 2010 | 9264 | 0.030 |
Why?
|
Exophthalmos | 1 | 2013 | 100 | 0.030 |
Why?
|
Disease Progression | 1 | 2010 | 13674 | 0.030 |
Why?
|
Sclera | 1 | 2014 | 189 | 0.030 |
Why?
|
Particulate Matter | 1 | 2023 | 2615 | 0.020 |
Why?
|
Magnetic Resonance Angiography | 1 | 2018 | 1434 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 1 | 2014 | 20776 | 0.020 |
Why?
|
Quality of Life | 2 | 2022 | 13510 | 0.020 |
Why?
|
General Surgery | 1 | 2022 | 1722 | 0.020 |
Why?
|
Hyperplasia | 1 | 2013 | 1154 | 0.020 |
Why?
|
Middle Aged | 4 | 2022 | 223737 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2022 | 3070 | 0.020 |
Why?
|
Education, Medical, Graduate | 1 | 2022 | 2422 | 0.020 |
Why?
|
Medicaid | 1 | 2023 | 2843 | 0.020 |
Why?
|
Socioeconomic Factors | 1 | 2024 | 7861 | 0.020 |
Why?
|
Risk Factors | 3 | 2024 | 74976 | 0.020 |
Why?
|
Eye | 1 | 2013 | 712 | 0.020 |
Why?
|
Thrombocytosis | 1 | 2009 | 88 | 0.020 |
Why?
|
Chronic Disease | 1 | 2023 | 9384 | 0.020 |
Why?
|
Neuropsychological Tests | 1 | 2021 | 7148 | 0.020 |
Why?
|
Case-Control Studies | 2 | 2018 | 22296 | 0.020 |
Why?
|
Prevalence | 1 | 2024 | 15879 | 0.020 |
Why?
|
Fundus Oculi | 1 | 2009 | 560 | 0.020 |
Why?
|
Registries | 1 | 2023 | 8384 | 0.020 |
Why?
|
Retina | 1 | 2017 | 2661 | 0.020 |
Why?
|
Proteomics | 1 | 2020 | 3914 | 0.020 |
Why?
|
Databases, Factual | 1 | 2022 | 8094 | 0.020 |
Why?
|
Massachusetts | 1 | 2019 | 8894 | 0.020 |
Why?
|
Primary Health Care | 1 | 2022 | 4748 | 0.020 |
Why?
|
Comorbidity | 1 | 2020 | 10592 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2017 | 10765 | 0.010 |
Why?
|
Incidence | 1 | 2023 | 21547 | 0.010 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2019 | 4056 | 0.010 |
Why?
|
Mutation | 2 | 2020 | 30266 | 0.010 |
Why?
|
Birefringence | 1 | 2003 | 54 | 0.010 |
Why?
|
Treatment Failure | 1 | 2009 | 2664 | 0.010 |
Why?
|
Functional Laterality | 1 | 2009 | 2267 | 0.010 |
Why?
|
Phenotype | 1 | 2020 | 16731 | 0.010 |
Why?
|
Postoperative Complications | 1 | 2024 | 15889 | 0.010 |
Why?
|
Electroencephalography | 1 | 2017 | 6317 | 0.010 |
Why?
|
Boston | 1 | 2014 | 9377 | 0.010 |
Why?
|
Automation | 1 | 2003 | 589 | 0.010 |
Why?
|
Algorithms | 1 | 2020 | 14201 | 0.010 |
Why?
|
Aged | 2 | 2023 | 171786 | 0.010 |
Why?
|
Cerebrovascular Circulation | 1 | 2009 | 2734 | 0.010 |
Why?
|
Age Factors | 1 | 2014 | 18435 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2017 | 26428 | 0.010 |
Why?
|
Equipment Design | 1 | 2003 | 3530 | 0.010 |
Why?
|
Time Factors | 1 | 2017 | 40261 | 0.010 |
Why?
|
Prognosis | 1 | 2014 | 30046 | 0.010 |
Why?
|
Hypertension | 1 | 2009 | 8617 | 0.000 |
Why?
|
Aged, 80 and over | 1 | 2009 | 59739 | 0.000 |
Why?
|
Concepts
(249)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(76)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_